Nanotechnology Databases

Comprehensive databases for nanomaterials, events, products,
companies, research labs, degree programs and publications

 

Nanobiotechnology and Nanomedicine Companies

 

Showing results 1 - 20 of 25 for companies in category Biotechnology in USA:

 
The company is commercializing novel instrumentation and services for rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to the sequencing of whole genomes and ultra-deep sequencing of target genes.
Altogen Biosystems develops polymer-, lipid-, and dendrimer-based transfection technology by applying expertise in molecular biology, combinatorial chemistry, and cell biology.
The Ambion brand encompasses a complete range of products for researchers whose work involves RNA. These include products for the isolation, detection, quantification, amplification, and characterization of RNA.
Amgen's heritage in cutting-edge molecular biology has led the development of protein therapeutics.
AMRI is a chemistry-based drug discovery, development and manufacturing company, focusing on small molecule prescription drugs.
This is a clinical-stage product-focused molecular imaging company that has assembled expertise and IP in the field of molecular brain imaging.
Blend Therapeutics is a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases. The company is pioneering an integrative way to discover molecular entities with new mechanisms of action purposely designed for our proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together they can make medicines more targeted, more effective and more tolerable.
The company develops new treatments for cancer based on a portfolio of delivery technologies including liposomes, polymers and nanotechnologies.
Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.
Ensemble Therapeutics is utilizing DNA Programmed Chemistry (DPC), an innovative method for creating new chemical bonds. Ensemble integrates DPC into a nanoscale selection system that combines chemistry, biology and informatics to discover novel compounds.
Develops and supplies molecular diagnostics products.
One of the world's foremost biotechnology companies, the company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing.
The company has active internal drug discovery programs focused on the identification of novel small molecule drugs for oncology, inflammation, HIV and diabetes.
A cell culture/biotech company making strides in enhancing organ preservation and cell culturing at both room temperature and through cryopreservation. The LIFOR® technology is the nanoparticle component of the solution, which carries the oxygen or any type of drug or nutrient that the developers wish to place into the nanoparticle.
The company is focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery.
NanoCor intends to use its proprietary Biological Nanoparticle technology platform and a proprietary, patent-protected gene to provide Chronic Heart Failure patients worldwide with an effective, economic, and safe alternative.
NanoLife Holdings is focused on its mission of the development of a Global Initiative, the commitment of the world's scientific, economic, and political prowess to Saving Lives from the Ravages of Cancer. NanoLife is facilitating advanced developments in radiotherapy for cancer.
Piercell is a nanotechnology venture that is developing a biomolecular delivery device that pierces into primary and other hard-to-transfect cells. Piercell's vision is to pave the path to cell therapy by enabling ex vivo DNA and RNA drug delivery into clinically relevant cells of patients.
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
 
 
left arrowBack to Nanotechnology Links Directory